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Tumorigenesis is a multi-step process that reflects intimate reciprocal interactions 
between epithelia and underlying stroma. However, tumor-initiating mechanisms 
coordinating transformation of both epithelial and stromal components are not defined. 
In humans and mice, initiation of colorectal cancer is universally associated with loss of 
guanylin and uroguanylin, the endogenous ligands for the tumor suppressor guanylyl 
cyclase C (GUCY2C), disrupting a network of homeostatic mechanisms along the crypt-
surface axis. Here, we reveal that silencing GUCY2C in human colon cancer cells 
increases Akt-dependent TGF-β secretion, activating fibroblasts through TGF-β type I 
receptors and Smad3 phosphorylation. In turn, activating TGF-β signaling induces 
fibroblasts to secrete hepatocyte growth factor (HGF), reciprocally driving colon cancer 
cell proliferation through cMET-dependent signaling. Elimination of GUCY2C signaling in 
mice (Gucy2c-/-) produces intestinal desmoplasia, with increased reactive 
myofibroblasts, which is suppressed by anti-TGF-β antibodies or genetic silencing of Akt.  
Thus, GUCY2C coordinates intestinal epithelial-mesenchymal homeostasis through 
reciprocal paracrine circuits mediated by TGF-β and HGF. In that context, GUCY2C 
signaling constitutes a direct link between the initiation of colorectal cancer and the 
induction of its associated desmoplastic stromal niche. The recent regulatory approval 
of oral GUCY2C ligands to treat chronic gastrointestinal disorders underscores the 
potential therapeutic opportunity for oral GUCY2C hormone replacement to prevent 




Tumorigenesis reflects an intimate collaboration between cancer cells and the 
supporting microenvironmental stroma (1-3). Genetic changes underlying malignant 
transformation corrupt circuits regulating epithelial-mesenchymal cross-talk that are 
essential for normal tissue organization, homeostasis, and regeneration (4). This 
reprogramming drives the co-evolution of epithelial cells and their supporting 
microenvironment, producing reactive stroma that allows tumor cells to acquire the 
hallmarks of cancer (2, 5, 6). 
The dynamic changes in cancer-associated stroma resemble the desmoplastic reaction 
of wound-healing, characterized by extracellular mesenchymal remodeling with 
increased matrix deposition and matrix metalloproteinase (MMP) activity (4). Tumor-
associated desmoplasia is supported primarily by the transformation of quiescent host 
fibroblasts into myofibroblasts (1, 2, 7, 8). While normal stroma contains few fibroblasts, 
there is an increase in activated myofibroblasts within the reactive stroma surrounding 
tumors (8). Induction of the myofibroblastic phenotype in quiescent fibroblasts is 
supported by the secretion of TGF-β by cancer cells (1, 3, 9). Reciprocally, 
myofibroblasts play an essential role in solid tumors by producing paracrine and 
juxtacrine factors, including HGF, that drive normal epithelial cells toward acquiring the 
malignant phenotype (1, 5, 6, 10-14). 
Paracrine cross-talk between epithelia and mesenchyme is essential to cancer 
progression and metastasis (15), but the precise signaling mechanisms linking tumor-
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initiating events to desmoplastic induction remain incompletely defined. For example 
the cell type coordinating epithelial and mesenchymal reprogramming at the initiation 
of transformation remains unknown (2, 8, 16). Thus, dissecting the individual stromal 
and epithelial contributions would define the paracrine signaling loops initiating and 
supporting carcinogenesis and provide new targets for tumor prevention and therapy. 
Guanylyl cyclase C (GUCY2C) is the intestinal isoform from the family of guanylyl cyclase 
transmembrane receptor enzymes that signal by producing cGMP (17). GUCY2C was 
first identified as the intestinal epithelial receptor regulating fluid and electrolyte 
transport in the secretory diarrhea induced by bacterial enterotoxins (ST) (17). Discovery 
of the endogenous paracrine hormones uroguanylin, in the small intestine, and guanylin, 
in the colorectum (18), revealed a role for GUCY2C in epithelial cell dynamics and the 
homeostatic balance of proliferation, metabolism, and differentiation that organizes the 
crypt-surface axis in the intestine (19-23). 
Notably, guanylin and uroguanylin are the most commonly lost gene products in 
intestinal tumorigenesis in animals and humans, and their expression is universally 
silenced at the earliest stages of transformation (24-27). Further, eliminating GUCY2C 
amplifies the tumorigenesis induced by carcinogens or gene mutations in mice (20, 21). 
Indeed, silencing GUCY2C activates the AKT-mTOR signaling axis, which imparts cell-
autonomous characteristics of transformation to intestinal epithelial cells, 
encompassing accelerated proliferation, reprogramming of metabolism from oxidative 
phosphorylation to aerobic glycolysis, and impaired DNA damage repair (19-23). 
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Moreover, oral administration of GUCY2C hormone attenuates the colorectal 
tumorigenesis induced by APC mutations in mice (25). GUCY2C has emerged as a novel 
intestinal tumor suppressor whose silencing through hormone loss universally 
contributes to the initiation and progression of colorectal cancer. 
In the heart, the natriuretic peptide receptor guanylyl cyclase A isoform (NPR1) is 
expressed in cardiomyocytes and establishes a homeostatic balance with the 
mesenchymal compartment (28, 29). Silencing cardiomyocyte NPR1 and cGMP signaling 
produces cardiac hypertrophy and elevated interstitial fibrosis (28, 29). In fact, increases 
in growth and fibrosis are disproportionate to and perhaps even independent of 
increases in blood pressure or volume, suggesting that NPR1 acts through local, 
paracrine pathways to suppress hypertrophy and desmoplasia (28, 29). The paracrine 
mechanisms mediating this cardiomyocyte-mesenchymal cross-talk remain incompletely 
characterized. However, based on this role of NPR1 and cGMP signaling in the heart, the 
present study explored whether the tumor suppressor GUCY2C and cGMP had 
homologous functions in the intestine, namely the maintenance of epithelial-
mesenchymal homeostasis whose corruption contributes to tumor-associated 
desmoplasia. 
MATERIALS AND METHODS 
Animal models 
Gucy2c-/- wild type littermate mice on the C57BL/6 background (generation 14) were 
bred, maintained, genotyped, and functionally characterized in accordance with the 
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Thomas Jefferson University Animal Care and Use guidelines (19-21). Akt1+/-Gucy2c+/+ 
and Akt1+/-Gucy2c-/- were bred from Akt1+/-Gucy2c+/-, genotyped and functionally 
characterized as described previously in accordance with the Thomas Jefferson 
University Animal Care and Use guidelines (21). Where indicated, animals received an IP 
dose (0.5 mg/kg) of IgG (Innovative Research, MI) or TGF-β-specific monoclonal 
antibody purified from the 1D11.16.8 hybridoma cell line (ATCC, VA) twice weekly for 10 
weeks. This regimen inhibits downstream canonical TGF-β signaling in intestine in 
C57BL/6 mice (30). 
Cell culture and fibroblast activation 
T84 and Caco2 human colon cancer cells were maintained and cultured in DMEM-F12 
and DMEM (Cellgro, VA) media supplemented with 10% FBS (21). CCD-18Co normal 
human intestinal fibroblasts were cultured and maintained in Eagle's Minimum Essential 
Medium (ATCC, VA). In studies of fibroblast induction, T84 or Caco2 cells were cultured 
in MEM Minimum Essential Medium (Cellgro) without FBS for 48 h. Then, completed 
growth media were conditioned by cancer cells for another 48 h, including either the 
GUCY2C ligand, ST (1 μM), or vehicle, PBS (21, 22). Conditioned media were centrifuged 
at maximum speed for 5 min to precipitate cancer cells and then diluted with 2 parts of 
Opti-MEM® GlutaMAX™ (Invitrogen, NY) to obtain a 1:3 dilution before applying to 
fibroblasts for 24 h. Notably, T84 and Caco2 cells express GUCY2C which mediates 
canonical downstream cGMP signaling upon ligand binding (19-21). In contrast, CCD-
18Co do not express GUCY2C and are unresponsive to ligands targeting that receptor. 
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Antibody treatment, TGF-β receptor inhibitors, and siRNA transfection 
In experiments exploring the role of cancer cell TGF-β in fibroblast activation, T84 or 
Caco2 cell-conditioned media was treated with a neutralizing antibody to TGF-β (30 
ng/µL) or control IgG (30 ng/µL). In some experiments, TGF-β produced by colon cancer 
cells was depleted from conditioned media with neutralizing antibody to TGF-β (30 
ng/µL) followed by immunoprecipitation with Dynabeads® Protein G (Invitrogen, VA). 
Cancer cell-derived TGF-β removed by immunoprecipitation was replaced with 
recombinant purified TGF-β (rTGF-β; R&D Systems, MN) at a concentration (10 ng/ml) 
corresponding to that produced by T84 cells, quantified by ELISA (R&D systems, MN). In 
experiments employing TGF-β receptor inhibitors, colon cancer cells were treated with 
PBS or 1 μM ST for 48 h before the conditioned media was transferred to CCD-18Co cells 
pretreated for 0.5 h with the TGF-β type I receptor inhibitor SB-505124 (50 nM, Sigma 
Aldrich). SB-505124 treatment continued in the conditioned media for the indicated 
times. In studies employing siRNA, colon cancer cells were transfected with TGF-β-
targeted or control siRNA (100 nM; ABI) by Amaxa® Electroporation (Lonza, NJ) 48 h 
before use in conditioned media transfer experiments, to permit adequate time for 
suppression of TGF-β expression. 
Akt activation and inhibition in cancer cells 
T84 were infected with adenovirus-expressing siAKT1 and GFP control for inhibition 
experiments, or adenovirus-expressing wtAKT1 and myrAKT1 for activation 
experiments, at 50% confluence using MOI’s of 100 at 48 h before GUCY2C activation 
11 
 
during starvation (21). Then, cells were washed and incubated in complete media with 1 
μM ST or PBS (control) for 48 h. The conditioned media was transferred to fibroblasts 
after dilution as described above. 
HGF production by fibroblasts and cMET activation 
Media conditioned by T84 cells with and without activation of GUCY2C signaling by 1 µm 
ST or PBS (control) for 48 h were used to induce fibroblast activation of CCD-18Co cells 
following incubation for 24 h. Then, fibroblast-conditioned media were transferred to 
HCT116 human colon cancer cells, which do not express GUCY2C and possess 
inactivating mutations in the TGF-β receptor (21, 31), and proliferation was quantified 
employing 3H-thymidine (21-23). HCT116 cells are particularly useful for quantifying the 
effects of fibroblast-derived HGF on colon cancer cell proliferation in the absence of 
confounding by GUCY2C or TGF-β ligands. In some experiments, media sequentially 
conditioned by human cancer cells and then by fibroblasts were treated with a 
neutralizing antibody to HGF or control IgG (20 µg/mL; R&D Systems, MN). Where 
indicated, HGF produced by fibroblasts was depleted from conditioned media with 
neutralizing antibody to HGF (20 µg/mL) followed by immunoprecipitation with 
Dynabeads® Protein G (Invitrogen, VA). Fibroblast-derived HGF depleted by 
immunoprecipitation was replaced with recombinant purified HGF (rHGF; 2.5 ng/ml; 
R&D Systems, MN). In some experiments, HCT116 cells were pre-treated with cMet 
Kinase Inhibitor III (500 nM; EMD Millipore, Germany), an inhibitor of cMET, the 
canonical receptor for HGF (32), for 5 min before incubations with conditioned media.  
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Immunoblot analyses and immunofluorescence 
Protein was extracted from cells and tissues in M-PER reagent supplemented with 
protease and phosphatase inhibitors (Thermal Scientific, TX) and quantified by 
immunoblot analysis employing antibodies to procollagen I (Sigma-Aldrich, MO); α-SMA 
and MMP-9 (Biomol, NY); and GAPDH and prolyl hydroxylase-β (Abcam, MA). Other 
antibodies were from Cell Signaling (MA). Anti-α-smooth muscle actin (α-SMA; Sigma-
Aldrich, MO), anti-collagen I and anti-β-catenin (Santa Cruz Biotechnology, CA) 
antibodies were used to stain fibroblasts and epithelial cells, respectively (1, 33). 
Expression levels were quantified by estimating the integrated density of the protein of 
interest and normalizing to the integrated density of the nucleus (DAPI).  Stained tissues 
were quantified in 5-15 crypt units in 5-10 sections in each mouse. 
Masson’s trichrome stain 
Tissue collected from mice were deparaffinized and stained with Weigert's iron 
hematoxylin solution and Biebrich scarlet-acid fuchsin, placed in phosphomolybdic/ 
polyphosphotungstic acid solution, and counterstained with Aniline blue (Dako, CA) or 
Masson’s Trichrome Stain Kit (Sigma-Aldrich, MO). The bottom of crypts was identified 
by the presence of Paneth cells. In Figure 1, the interstitial thickness was calculated as: 
area of the blue stain divided by the length of the underlying muscle layer, quantified in 
Image J. In Figure 6, the interstitial thickness displays the shortest distance between the 
bottom of the crypt and the muscle layer. In both cases, pixels were converted back to 
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metric dimensions. Quantification represents data from 5-10 crypt units in 5-10 sections 
per mouse. 
Hydroxyproline assay 
Tissue was freeze-dried, homogenized, and hydrolyzed in 0.5 mL of 5 M HCl for 16 h at 
116o C. Samples were dried, dissolved in distilled water, and hydroxyproline quantified 
using a colorimetric demethylmethylene blue assay (Sigma-Aldrich, MO) (34). 
Collagen contractility assay 
CCD-18Co cells and Type I Collagen (Sigma-Aldrich, MO) dissolved in acetic acid (0.1%) 
was used to access functional differences in contractility between quiescent fibroblasts 
and fibroblasts (35). After solutions were neutralized with NaOH (1 µM), cells were 
suspended in the collagen, plated, and cancer cell-conditioned media was added (35). 
Quantitative RT-PCR 
Total RNA was subjected to one-step RT-PCR using TaqMan® EZ RT-PCR Core Reagents 
and specific primer/probes for TaqMan® Gene Expression Assays in an ABI 7000 
(Applied Biosystems, CA) (36). Relative expression was calculated using the 2-∆∆CT 
method with GAPDH or β-actin as reference (36). 
Electron microscopy 
Intestinal samples were collected, processed, fixed and embedded as previously 
described (21). Ninety nm sections were imaged with a JEOL-1010 electron microscope 




Statistical significance was determined by unpaired two-tailed Student’s t test. Unless 
otherwise indicated, results represent means ± SEM from >3 animals or >3 experiments 
performed in triplicate. 
RESULTS 
GUCY2C in epithelial cells opposes desmoplasia 
The absence of epithelial GUCY2C signaling in Gucy2c knockout mice (Gucy2c-/-) 
produced submucosal hypertrophy (Fig. 1A1, 1A2), with canonical characteristics of 
desmoplasia (1, 2, 5, 7). Specifically, stromal expansion was associated with increased 
deposition of the matrix components tenascin C (Fig. 1B1), fibronectin (Fig. 1B2), and 
collagen I (Fig. 1B3, 1B4), which is a hallmark of malignancy-associated desmoplasia (37). 
Also, absence of epithelial GUCY2C signaling increased submucosal fibroblast content, 
particularly in the pericryptal sheath (Fig. 1C1, 1C2), an anatomical location driving 
mesenchymally-directed epithelial cell proliferation (8, 38). Further, these cells were 
identified as fibroblasts, reflected by increased transcription (Fig. 1D) and translation 
(Fig. 1E) of canonical markers of fibroblast activation (1, 2, 5, 7). Thus, this submucosal 
hypertrophy in Gucy2c-/- mice recapitulated the desmoplastic reaction in human 
colorectal cancer. 
Moreover, in vitro studies with human colon cancer cells and fibroblasts further 
demonstrated that fibroblast activation is modulated by GUCY2C signaling. Media 
conditioned by T84 human colon cancer cells in the presence or absence of GUCY2C-
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activating ligand (ST) were collected and used to treat CCD-18Co human fibroblasts. T84 
cells express GUCY2C, which mediates canonical downstream cGMP signaling upon 
ligand binding (20-22). In contrast, CCD-18Co cells do not express GUCY2C and are 
unresponsive to ligands targeting that receptor. As quantified by activated fibroblast 
numbers (Fig. 2A), matrix synthesis (Fig. 2B), and contraction of collagen (Fig. 2C) (1, 7, 8, 
35), conditioned media from T84 cells without ST treatment produced fibroblast 
activation, which was markedly reduced by ST. 
Epithelial GUCY2C regulates fibroblast activation through TGF-β secretion 
TGF-β is an established mediator of fibroblast activation and desmoplasia whose 
secretion characterizes the entire developmental continuum of solid tumors in animals 
and humans (1, 2, 7, 8, 11). GUCY2C activation by ST did not alter transcription of TGF-β, 
but markedly increased TGF-β retention and decreased TGF-β secretion, by cancer cells 
(Fig. 3A, B). In a series of conditioned-media experiments, media conditioned by T84 
human colon cancer cells were collected and used to treat CCD-18Co human fibroblasts. 
Reducing TGF-β mRNA expression and protein secretion in cancer cells with siRNA 
(Fig.3A) mimicked ST-induced GUCY2C signaling and opposed fibroblast activation, 
including collagen contractility and translation of biomarkers of activation, by 
conditioned media (Fig. 3C-D). Inhibiting fibroblast TGF-β type I receptors with TGF-β 
receptor inhibitor SB-505124 also mimicked ST-induced GUCY2C signaling and opposed 
fibroblast activation by conditioned media (Fig. 3E). Further, cancer cell-conditioned 
media activated fibroblast TGF-β receptor signaling through phosphorylation of the TGF-
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β signaling target Smad-3, and GUCY2C signaling in cancer cells blocked that effect (Fig. 
3F). 
Additionally, a neutralizing antibody to secreted TGF-β reduced both the fibroblast 
activation (Fig. 4A) and the Smad-3 phosphorylation (Fig. 4B) induced by cancer cell-
conditioned media. The effects of neutralizing antibodies on fibroblast activation and 
TGF-β signaling were abrogated when TGF-β was re-introduced by adding recombinant 
purified TGF-β (rTGB-β) (Fig. 4A-B). To reinforce these in vitro findings, in vivo studies 
were conducted in which Gucy2c-/- mice were treated with TGF-β neutralizing antibodies. 
Antibody administration reversed the submucosal desmoplasia (Fig. 4C), reducing 
interstitial thickness (Fig. 4C), total collagen deposition (Fig. 4D), Smad-3 
phosphorylation (Fig. 4E), and fibroblast activation (Fig. 4F). These data reveal that 
GUCY2C mediates an efferent mucosal paracrine limb which modulates epithelial TGF-β 
secretion and fibroblast activation through TGF-β receptors and Smad-3 
phosphorylation, and thereby shapes the submucosal microenvironment to oppose the 
desmoplastic reaction. 
GUCY2C regulates epithelial TGF-β secretion and fibroblast activation through Akt 
GUCY2C regulates epithelial cell homeostasis and suppresses tumorigenesis through the 
Akt signaling pathway (21). Notably, studies have also demonstrated that Akt regulates 
the secretion of TGF-β in mechanisms remodeling the stroma microenvironment (39). In 
vitro, elimination of AKT expression with siRNA (siAkt) mimicked ST-induced GUCY2C 
signaling, and replicated the effects of ST on cancer cell secretion of TGF-β (Fig. 5A) and 
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fibroblast activation (Fig. 5B). Conversely, constitutive activation of AKT by 
myristoylation (myrAKT) (21) mimicked the absence of GUCY2C signaling, and blocked 
the reverting effects of ST, leading to the promotion of TGF-β secretion (Fig. 5C). 
Moreover, reducing AKT expression through gene disruption in vivo subdued the 
stromal remodeling produced by silencing GUCY2C (Fig. 5D). These observations support 
a model in which, as in other homeostatic processes like proliferation and metabolism 
(19-23), the regulation of epithelial TGF-β secretion, fibroblast activation, and stromal 
remodeling by GUCY2C is mediated through epithelial AKT signaling. 
GUCY2C reciprocally regulates fibroblast-dependent epithelial cell hyperproliferation 
Beyond the contribution of efferent mucosal signals to submucosal fibroblasts, 
mechanisms by which this microenvironmental re-programming reciprocally contributes 
to an afferent paracrine loop modulating epithelial hyperproliferation remain 
incompletely defined (1, 2, 7, 8). To investigate this afferent loop, we conducted a series 
of in vitro experiments employing sequentially conditioned media: media conditioned 
by human colon cancer cells were collected and used to activate human fibroblasts; and 
the media conditioned by these activated fibroblasts were collected and applied to 
human colon cancer cells. 
In one study, CCD-18Co human fibroblasts were activated by TGF-β at different 
concentrations, and the conditioned media was collected. Application of this fibroblast-
conditioned media drove proliferation of human colon cancer cells, as quantified by 3H-
thymidine incorporation, in a TGF-β concentration-dependent manner (Fig. 6A). 
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Similarly, colon cancer cell-conditioned media activated fibroblasts, which, in turn, 
produced conditioned media that reciprocally drove the proliferation of HCT116 human 
colon cancer cells, which do not express GUCY2C or TGF-β receptors (Fig. 6B). However, 
the ability of fibroblasts to drive epithelial proliferation was eliminated by pre-treating 
epithelial cell-conditioned media with TGF-β neutralizing antibodies (Fig. 6B). Further, 
when treated with media from cancer cells incubated with the GUCY2C ligand ST, 
fibroblasts failed to drive epithelial proliferation (Fig. 6B). Exogenous supplementation 
of fibroblasts with rTGF-βreconstituted the fibroblast-conditioned media’s capacity to 
induce epithelial proliferation, abrogating the effects of TGF-β neutralizing antibody or 
GUCY2C signaling (Fig. 6B). These results reveal that GUCY2C signaling regulates the 
epithelial secretion of TGF-β, which not only activates fibroblasts, but also induces them 
to release factors that reciprocally feed back to drive epithelial cell proliferation. 
Desmoplastic fibroblast activation is associated with expression of the mitogen HGF (Fig. 
1D), a mediator of microenvironmental influences on epithelial cells, including stromal 
induction of epithelial proliferation (1, 2, 7, 8, 11, 40). In agreement with previous 
studies, HGF induced HCT116 human colon cancer cells to proliferate in a concentration-
dependent fashion (Fig. 6C). Further, pretreatment of cancer cells with ST reduced HGF 
mRNA and protein production from fibroblasts that were activated by TGF-β secreted 
from colon cancer cells , (Fig. 6D). In turn, those fibroblast-conditioned media activated 
cMET, the canonical receptor for HGF (32), in HCT116 cells. This effect was eliminated by 
pre-treating fibroblast-conditioned media with HGF neutralizing antibody, an effect 
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reversed by recombinant HGF (rHGF; Fig. 6E). Moreover, ST-activated GUCY2C signaling 
in epithelial cells reduced their ability to induce fibroblasts to drive colon cancer cell 
proliferation (Fig. 6B and F). This effect was replicated by adding HGF neutralizing 
antibodies or an inhibitor of cMET to the fibroblast-conditioned media and blocked by 
rHGF (Fig. 6F). These observations suggest a model in which GUCY2C mediates an 
efferent paracrine circuit regulating the epithelial secretion of TGF-β, and the 
consequent activation of fibroblasts. In turn, TGF-β ultimately induces a reciprocal 
afferent paracrine circuit in which the activated stromal fibroblasts produce HGF, which 
promotes cMET-dependent epithelial cell proliferation (Fig. 7). 
DISCUSSION 
Undergoing continuous cycles of regeneration, the intestinal crypt-surface axis is 
dynamic. GUCY2C signaling organizes the spatiotemporal tissue pattern, maintaining 
homeostasis along this axis (19-23). Specifically, GUCY2C controls epithelial cell 
proliferation by regulating the expression of critical mediators that slow the cell cycle 
(19-23). Further, GUCY2C and cGMP signaling establish cell fate by promoting the 
differentiation of epithelial cells in the secretory lineage, which includes Paneth and 
goblet cells (19). These effects define the balance between the relative sizes of 
proliferating and differentiated cell compartments along the crypt-surface axis (19-23). 
Moreover, GUCY2C is key in matching the appropriate metabolic program to the 
functional demands along this axis. Namely, low GUCY2C signaling in the crypt favors 
glycolysis to support rapidly proliferating transit-amplifying cells (21). Conversely, robust 
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GUCY2C signaling in the villus/surface compartment shifts the metabolic program to 
mitochondrial oxidative phosphorylation, the canonical source for ATP generation in 
differentiated cells (21). 
The present study expands the homeostatic role for GUCY2C beyond these cell-
autonomous functions to coordinating the paracrine cross-talk between the epithelial 
and mesenchymal compartments that is essential for normal tissue patterning (1, 3, 40). 
Indeed, it suggests a model in which mucosal GUCY2C coordinates bi-directional 
epithelial-mesenchymal cross-talk in the intestine (Fig. 7). In this model, GUCY2C 
signaling in the epithelium opposes an efferent mucosal paracrine loop by suppressing 
the epithelial secretion of TGF-β, the activation of submucosal fibroblasts, and the 
desmoplastic reaction. In turn, the suppression of fibroblast activation by GUCY2C-
regulated paracrine signaling reduces HGF, silencing an afferent loop that drives 
epithelial cell proliferation. Notably, this GUCY2C function in the intestinal mucosa 
recapitulates that of the related guanylyl cyclase isoform NPR1 in cardiomyocytes (28, 
29). NPR1 coordinates mesenchymal homeostasis in the heart, and its silencing 
produces cardiac fibrosis that is independent of increases in blood pressure (28, 29). 
Targeted NPR1 knockout (Npr1-/-) produces local extracellular matrix remodeling in 
paracrine pathways involving increased TGF-β (28, 29). 
The discovery that GUCY2C underlies spatiotemporal patterning along the crypt-surface 
axis expands its role in the homeostatic maintenance of the intestinal mucosae (19, 22). 
Moreover, it highlights the emergence of GUCY2C as a tumor suppressor universally 
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silenced in the initiation and progression of colorectal cancer (20, 21, 23). The 
endogenous ligands for GUCY2C, guanylin and uroguanylin, are the most commonly lost 
gene products in intestinal tumorigenesis and these ligands are lost at the earliest 
stages of transformation (24-27). Loss of paracrine ligands silences GUCY2C which, in 
turn, activates AKT and mTOR, well-established oncogenes driving tumorigenesis in 
many tissues (21). Indeed, eliminating GUCY2C signaling amplifies intestinal 
tumorigenesis induced by carcinogens or gene mutations (20). 
Silencing GUCY2C establishes a number of cell-autonomous mechanisms underlying 
epithelial cell tumorigenesis (6). Thus, the cell cycle is accelerated, expanding the 
proliferating crypt compartment (19-23). Further, metabolic programming is shifted 
from mitochondrial oxidative phosphorylation to aerobic glycolysis characterizing the 
Warburg metabolic phenotype (21). Moreover, genomic instability is accelerated by 
over-production of reactive oxygen species and exacerbated by a decrease in the ability 
to repair DNA damage (20, 21). Indeed, eliminating GUCY2C signaling induces Apc loss of 
heterozygosity in Apcmin mice and the acquisition of mutations in β-catenin in mice 
treated with the carcinogen AOM, encompassing the genomic changes underlying 
nearly all sporadic intestinal tumorigenesis in humans (20). The present study expands 
the role of GUCY2C as a tumor suppressor whose silencing not only corrupts cell-
autonomous pathways regulating epithelial transformation, but also epithelial-
mesenchymal paracrine circuits underlying fibroblast activation and desmoplasia, a 
process which universally contributes to tumorigenesis in most tissues (2, 5, 6). 
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While interactions between tumor cells and the desmoplastic stroma are essential for 
cancer progression, invasion, metastasis, and the evolution of therapeutic resistance, 
the relative contributions of each compartment to tumor initiation remains undefined (1, 
2, 5, 16). The oncogenomic model of cancer suggests that tumors initiate and evolve by 
accumulating mutations, which alter critical signaling pathways regulating cell-
autonomous homeostatic functions, which ultimately lead to genomic instability and 
acquisition of invasive and metastatic phenotypes (6, 41-43). In this model, the 
mesenchymal compartment is dependent and reactive, shaped by the epithelial tumor 
to support cancer evolution. An alternate hypothesis suggests that, in some cases, 
stroma could be the pathophysiological initiator of tumorigenesis in dependent normal 
epithelial cells. Mice in which TGF-β receptors are silenced selectively in stromal 
fibroblasts develop neoplasia in the prostate and stomach (10, 44). Similarly, genetic 
models of HGF over-expression in fibroblasts are characterized by mammary 
tumorigenesis (45). Additionally, mutations of tumor suppressor genes in stromal 
fibroblasts drive the development of prostate tumors (46). This mechanistic debate 
concerning which compartment “leads” transformation has not yet been resolved (2, 5). 
The present study, in the context of GUCY2C silencing as one of the earliest changes 
underlying intestinal neoplasia (24-27), suggests that epithelial cell transformation leads 
tumor initiation in intestine by corrupting cell-autonomous (19-23) and non-cell-




Beyond this question of compartmental hierarchy, the relationship between canonical 
networks whose corruption initiates neoplasia, and reciprocal paracrine signaling axes 
organizing epithelial-mesenchymal cross-talk producing desmoplasia, remains undefined. 
For example, nearly all sporadic colorectal tumors harbor mutations in the WNT 
signaling pathway, primarily in APC (about 80%) or β-catenin (about 15%), which drive 
cell-autonomous changes in epithelia (41, 43, 47). However, the precise linkages 
between corrupted WNT signaling pathways underlying tumorigenesis and mechanisms 
coordinating desmoplasia characterizing colorectal cancer remain unknown. The 
present study offers a mechanistic explanation for coordination of epithelial 
transformation and the development of the desmoplastic reaction in colorectal cancer. 
Indeed, silencing GUCY2C in epithelial cells appears to be one of the earliest universal 
changes in colorectal carcinogenesis (24-27), with the ability to promote genomic 
instability and mutations in WNT signaling pathway intermediates (20). In this model, 
silencing the GUCY2C tumor suppressor early in transformation corrupts cell-
autonomous functions that are essential for transformation, including proliferation, 
metabolism, and DNA damage and repair (19-23). Moreover, the present study reveals 
that silencing GUCY2C simultaneously initiates AKT-dependent paracrine signaling 
through increased epithelial cell TGF-β secretion, activating fibroblasts that reshape the 
mesenchymal matrix compartment, producing the desmoplastic reaction promoting 
colorectal tumor invasion and progression. 
24 
 
There continues to be intense interest in elucidating the precise compartmental 
contributions, and their sequence, underlying epithelial-mesenchymal cross-talk 
contributing to neoplasia (16). Deconvoluting this spatiotemporal signaling sequence 
could provide therapeutic targets that disrupt the mutually reinforcing 
intercompartmental cycle essential for tumor initiation, progression, invasion, and 
metastasis (1, 2, 4, 5, 8, 16). This challenge is underscored by the incompletely 
understood role of TGF-β in tumorigenesis, sometimes referred to as the “TGF-β 
Paradox” (11, 48, 49). On the one hand, TGF-β has potent anti-proliferative properties in 
epithelial cells, and silencing tumor cell TGF-β receptors by mutation is a key genomic 
event mediating progression of colorectal tumorigenesis (41). On the other hand, TGF-β 
is one of the most potent drivers of quiescent fibroblast transformation to the fibroblast 
phenotype, although the precise compartment producing this cytokine driving 
desmoplasia remains uncertain (1, 2, 5, 8). Moreover, the activity of TGF-β on the 
stroma can promote tumor initiation, progression, and metastasis (50). Similarly, 
although HGF, which drives epithelial proliferation through cMET, is produced by 
fibroblasts in desmoplasia, the events inducing that production remain uncharacterized 
in most tumors (1, 2, 5, 8). In that context, the present study provides insight into the 
spatiotemporal sequence of signaling interactions coordinating events that drive tumor 
initiation and progression in epithelia and stroma in colorectal cancer. It suggests a 
model in which the earliest stages of tumorigenesis initiate, at least in part, by silencing 
GUCY2C, reflecting loss of ligand expression (24-27). Eliminating cGMP signaling in 
intestinal epithelial cells not only drives cell-autonomous changes coincident with 
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transformation (19-23), but also amplifies epithelial secretion of TGF-β, creating an 
efferent signal driving fibroblast activation and desmoplasia in adjacent stroma. In turn, 
fibroblasts activated by epithelial cell TGF-β produce HGF, creating a reciprocal afferent 
cytokine circuit with the potential to signal back to the epithelial compartment through 
cMET. In more advanced stages of transformation, characterized by loss of TGF-β 
signaling and its cell cycle suppression in epithelia (41, 48, 49), the potential of this 
reciprocal afferent HGF circuit is realized, further amplifying proliferation driving the 
progression of tumorigenesis. 
Epithelial cell GUCY2C signaling is one component of a program establishing and 
maintaining the intestinal crypt-surface axis through continuous waves of physiological 
regeneration. Beyond this role in normal tissue patterning, loss of guanylin and 
uroguanylin at the earliest stages of premalignancy suggests a novel model of intestinal 
tumorigenesis, initiating as a disease of tissue-specific paracrine hormone insufficiency 
(24-27). The resultant silencing of the GUCY2C tumor suppressor produces maladaptive 
amplification of survival circuits producing DNA damage and mutations contributing to 
the cell-autonomous basis of colorectal cancer (19-23). Moreover, these changes in 
epithelial transformation are coordinated with simultaneous changes in cytokine 
signaling mediating the desmoplastic reaction which, reciprocally, drives epithelial 
proliferation. This unique model of intestinal transformation as a paracrine hormone 
deficiency coordinating epithelial-mesenchymal transformation has substantial 
implications for the prevention and treatment of colorectal cancer. Indeed, GUCY2C is 
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over-expressed by intestinal tumors compared to normal adjacent tissues (36). Early loss 
of hormones with compensatory over-expression of receptors offers a unique 
therapeutic window preceding the corruption of epithelial survival pathways and 
stromal reactivity to prevent maladaptive reprogramming and the evolution of cancer 
through oral GUCY2C hormone replacement therapy (25). These considerations 
highlight the potential translational opportunities for oral GUCY2C paracrine hormone 
supplementation as a novel strategy that could contribute to the prevention of 
colorectal cancer, underscored by the recent FDA approval and commercial availability 
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Fig. 1. Silencing epithelial GUCY2C promotes intestinal desmoplasia and stromal 
fibroblast activation in mice. (A1) Masson’s Trichrome stain reveals submucosal 
hypertrophy in Gucy2c-/-, compared to wild type Gucy2c+/+, mice, associated with (A2) 
increased interstitial thickness and (B) matrix deposition, including (B1) tenascin C, (B2) 
fibronectin, quantified by immunofluorescence (IF) [Green, fibronectin; Red, ß-catenin; 
Blue, DAPI; bottom of crypt is determined by presence of β-catenin in nucleus (arrow)] 
and (B3) collagen, quantified by hydroxyproline analysis, and (B4) direct visualization by 
electron microscopy (n≥3 mice). (C1) Fibroblasts were visualized by α-smooth muscle 
actin (α-SMA) immunohistochemistry and (C2) quantified in 10 sections/mouse and 10 
crypts/section (n=5 mice). Fibroblast activation in Gucy2c-/-, compared to Gucy2c+/+ 
mice, was associated with increased expression of (D) mRNA [Col, collagen I; HGF, 
hepatocyte growth factor] and (E) protein [ProCol I, procollagen I; TIMP-1, tissue 
inhibitor of metalloproteinase-1; α-SMA, α-smooth muscle actin; MMP-9, matrix 
metalloproteinase-9] markers of fibroblasts. Unless otherwise indicated, data represent 
means of n=5 ± SEM. In (E), statistics reflect comparisons to Gucy2c+/+. *, p<0.05, **, 
p<0.01. 
Fig. 2. Activation of GUCY2C signaling prevents fibroblast activation. CCD-18Co human 
fibroblasts were incubated with media conditioned by T84 or Caco 2 human colon 
cancer cells, which both express GUCY2C, pretreated with or without 1 µM ST for 48 h 
and fibroblast activation was quantified by (A) enumeration of fibroblast activation by α-
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SMA immunofluorescence [red, α-SMA; blue, DAPI], (B) immunoblot analysis of 
fibroblast markers [PHD, prolyl hydroxylase; Pro-Col I, procollagen I], (C) fibroblast 
contraction of collagen gels [Red circle indicates contracted gel area]. Data represent 
means of n=3 experiments ± SEM in (A-C). Data in (C) represent the percent reduction in 
gel surface area induced by contraction. * p<0.05, ** p<0.01. 
Fig. 3. TGF-β mediates GUCY2C-dependent colon cancer cell regulation of fibroblast 
activation in vitro. (A) Effect of GUCY2C signaling on (A1) TGF-β mRNA expression, 
quantified by RT-PCR, or (A2) protein secretion, quantified by ELISA, by T84 human 
colon cancer cells. (A) Effect of TGF-β1-specific siRNAs (siTGF1 and siTGF2) on TGF-β1 
mRNA (qRT-PCR) expression and secretion (ELISA) by T84 cells. (B) Effect of GUCY2C, 
induced by ST (1 µM ST, 48 h), to regulate TGF-β secretion, quantified by ELISA, in T84 
human colon cancer cell. (C) Effect of TGF-β1-specific siRNAs on the ability of T84 cells 
pretreated with PBS or ST (1 µM ST, 48 h) to condition media quantified by (C1) 
fibroblast activation by confocal microscopy of α-SMA immunocytochemistry (activated 
fibroblasts) and (C2) fibroblast contraction of collagen gels (relative contractility). (D) 
Effect of TGF-β1-specific siRNA on the ability of T84 cells pretreated with PBS or ST (1 
µM ST, 48 h) to condition media, quantified by fibroblast PHD or α-SMA expression by 
immunoblot analysis [None, no siRNA; CTR (control), Scrambled siRNA; siTGF, TGF-β1 
siRNA]. (E) Effect of SB-505124, a selective inhibitor of TGF-β type I receptors, on the 
ability of CCD-18Co human fibroblasts to be activated by media conditioned by T84 
human colon cancer cells pretreated with PBS (control) or the GUYC2C ligand ST. (F) 
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Smad3 phosphorylation in fibroblasts activated by colon cancer cell-conditioned media 
[tSmad3, total Smad 3; pSmad3, phosphorylated Smad3]. Data represent means of n>3 
experiments ± SEM. *, p<0.05; **, p<0.01, or n.s. p>0.05. 
Fig. 4. TGF-β eliminates fibroblast activation in vitro and desmoplasia induced by 
silencing epithelial cell GUCY2C in mice. Media conditioned by T84 human colon cancer 
cells incubated with PBS (control) or ST (1 µM, 48 h) were treated with control IgG or 
neutralizing anti-TGF-β monoclonal antibody. In some experiments, T84 cell-derived 
TGF-β bound to neutralizing antibody was depleted using Protein G immunoaffinity 
beads and replaced with recombinant purified TGF-β (rTGF-β). Processed media were 
incubated with CCD-18Co human fibroblasts followed by quantification of (A) fibroblast 
activation by α-SMA immunocytochemistry and (B) phosphorylation of Smad3 by 
immunoblot analysis. Colon cancer cell-conditioned media were treated with: IgG, 
control; TGF-β Ab, anti-TGF-β antibody (30 µg/mL); rTGF-β, depletion of TGF-β-anti-TGF-
β complexes with protein G immunoaffinity beads followed by replacement with 
recombinant TGF-β (10 ng/mL). In (C-F), Gucy2c+/+ and Gucy2c-/- mice were treated with 
IgG or anti-TGF-β monoclonal antibody (0.5 mg/kg) IP twice weekly for ten weeks to 
neutralize soluble TGF-β followed by quantification of intestinal (C) matrix deposition, 
(D) collagen content, (E) Smad3 phosphorylation, and (F) fibroblast activation. Data 
represent means of n>4 experiments ± SEM *, p<0.05, **, p<0.01, or n.s., p>0.05. 
Fig. 5. GUCY2C regulates epithelial cell TGF-β secretion, fibroblast activation and 
desmoplasia through AKT. Fig. 5. GUCY2C regulates epithelial cell TGF-β secretion, 
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fibroblast activation and desmoplasia through AKT. (A) TGF-β protein secretion from 
colon cancer cells was quantified by ELISA. Cells were infected by adenovirus delivering 
GFP (control) or siAKT (siRNA targeting AKT). The effect of siAKT was confirmed by 
immunoblotting for AKT phosphorylated at ser473 (pAKT). (B) Effect of siAkt on the 
ability of T84 cells pretreated with PBS or ST (1 µM ST, 48 h) to condition media 
quantified by myofibroblast activation by α-SMA immunofluorescence [red, α-SMA; 
blue, DAPI; green, phospho-smad3]. (C) TGF-β protein secretion from cells infected with 
adenovirus delivering wild type AKT (wtAKT) or myristoylated AKT (myrAKT). Effect of 
myrAKT was confirmed by immunoblotting for pAKT. (D) Masson’s Trichrome stain for 
quantification of submucosal matrix thickness. In (A-C), data represent means of n>3 
experiments ± SEM. In (D) each point represents one mouse. *, p<0.05, **, p<0.01, or 
n.s., p>0.05. 
Fig. 6. Myofibroblast HGF production is controlled by epithelial cell GUCY2C and 
mediates afferent circuits regulating colon cancer cell proliferation. (A) TGF-β induces 
CCD-18Co human fibroblasts to produce paracrine substances in conditioned media 
driving T84 human colon cancer cell proliferation in a concentration-dependent fashion, 
quantified by 3H-thymidine incorporation. (B) Media conditioned by T84 human colon 
cancer cells incubated with PBS (control) or ST (1 µM, 48 h) were treated with control 
IgG or neutralizing anti-TGF-β monoclonal antibody, with or without replacement with 
rTGF-β. These media conditioned by T84 cells and processed as described were 
incubated with CCD-18Co human fibroblasts. Media sequentially conditioned by T84 
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cells and fibroblasts were then incubated with HCT116 human colon cancer cells which 
do not express GUCY2C or TGF-β receptors, followed by quantification of proliferation 
by 3H-thymidine incorporation. [Prior to conditioning by fibroblasts, T84 cell-conditioned 
media were treated with: IgG, control; TGF-β Ab, anti-TGF-β antibody (10 µg/mL); rTGF-
β, depletion of TGF-β by immunoprecipitation followed by replacement with rTGF-β (5 
ng/mL)]. (C) HGF induces HCT116 human colon cancer cell proliferation in a 
concentration-dependent fashion, quantified by 3H-thymidine incorporation. (D) ST (1 
µM, 48 h) pretreatment attenuates media conditioned by T84 colon cancer cells to 
induce HGF mRNA (left) and protein (right) expression in CCD-18Co human fibroblasts, 
quantified by RT-PCR and ELISA, respectively. (E) HGF secreted by CCD-18Co human 
fibroblasts activated by media conditioned by T84 human colon cancer cells treated with 
PBS or ST (1 µM, 48 h) activates cMET in HCT116 human colon cancer cells. cMET 
activation was quantified by immunoblotting for phosphorylation of cMET at 
Tyr1234/1235. Before addition to HCT116 cells, CCD-18Co cell-conditioned media were 
treated with: IgG, control; HGF neutralizing antibody (HGF nAb, 20 µg/mL); rHGF, 
depletion of HGF by immunoprecipitation followed by replacement with rHGF (1 
ng/mL)]. (F) HGF secreted by CCD-18Co human fibroblasts activated by media 
conditioned by T84 human colon cancer cells treated with PBS or ST (1 µM, 48 h) 
induces HCT116 colon cancer cell proliferation through cMET. Before addition to 
HCT116 colon cancer cells, conditioned media were treated with: IgG, control; HGF Ab, 
anti-HGF neutralizing antibody (20 µg/mL); rHGF, depletion of HGF-anti-HGF complexes 
by immunoprecipitation followed by replacement with recombinant HGF (2.5 ng/mL)]. 
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In some experiments, cMET was inhibited by cMet Kinase Inhibitor III (500 nM; cMET 
Inhibitor). Processed media were then incubated with HCT116 human colon cancer cells, 
followed by quantification of proliferation by 3H-thymidine incorporation. Data in 6A, 
6B, 6C, and 6F are representative of >3 experiments. Data in 6D and 6E represent means 
of n≥3 experiments ± SEM. p<0.05; **, p<0.01, or n.s. p>0.05. 
Fig. 7. Model of GUCY2C signaling effects on tumor microenvironment. GUCY2C 
hormones, guanylin and uroguanylin, secreted by normal epithelial cells (blue) maintain 
a homeostatic balance between the mucosa and fibroblasts in underlying stroma, 
mediated by epithelial cell GUCY2C. Silencing of GUCY2C through loss of ligand 
expression, a universal early event in tumorigenesis, induces transforming epithelial 
cells (pink) to secrete TGF-β (purple bubbles) which activates fibroblasts. In turn, 
activated fibroblasts have the ability to promote tumor cell proliferation by HGF (pink 
bubbles). 
